Therapeutic antibodies for autoimmunity and inflammation
- PMID: 20414204
- DOI: 10.1038/nri2761
Therapeutic antibodies for autoimmunity and inflammation
Abstract
The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.
Similar articles
-
A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.J Biol Chem. 2018 Jun 15;293(24):9326-9334. doi: 10.1074/jbc.M117.818559. Epub 2018 Apr 20. J Biol Chem. 2018. PMID: 29678878 Free PMC article.
-
Strategies and challenges for the next generation of therapeutic antibodies.Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747. Nat Rev Immunol. 2010. PMID: 20414207 Review.
-
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date.BioDrugs. 2020 Apr;34(2):111-119. doi: 10.1007/s40259-019-00400-2. BioDrugs. 2020. PMID: 31916225 Review.
-
The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE.Autoimmun Rev. 2012 Mar;11(5):373. doi: 10.1016/j.autrev.2011.01.002. Epub 2011 Jan 9. Autoimmun Rev. 2012. PMID: 21224014 No abstract available.
-
[Biological response modifiers in the treatment of immunoinflammatory diseases].Ugeskr Laeger. 2008 Jun 9;170(24):2120-6. Ugeskr Laeger. 2008. PMID: 18565292 Review. Danish.
Cited by
-
Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis.Front Immunol. 2020 Aug 18;11:1855. doi: 10.3389/fimmu.2020.01855. eCollection 2020. Front Immunol. 2020. PMID: 32973764 Free PMC article.
-
Glycosylation alterations in lung and brain cancer.Adv Cancer Res. 2015;126:305-44. doi: 10.1016/bs.acr.2014.11.007. Epub 2015 Feb 7. Adv Cancer Res. 2015. PMID: 25727152 Free PMC article. Review.
-
Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.Hum Vaccin Immunother. 2013 Nov;9(11):2434-44. doi: 10.4161/hv.25596. Epub 2013 Jul 8. Hum Vaccin Immunother. 2013. PMID: 23836278 Free PMC article.
-
Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process.Protein Eng Des Sel. 2015 Sep;28(9):269-79. doi: 10.1093/protein/gzv029. Epub 2015 Jun 30. Protein Eng Des Sel. 2015. PMID: 26134501 Free PMC article.
-
The NMDA Receptor Antibody Paradox: A Possible Approach to Developing Immunotherapies Targeting the NMDA Receptor.Front Neurol. 2020 Jul 3;11:635. doi: 10.3389/fneur.2020.00635. eCollection 2020. Front Neurol. 2020. PMID: 32719654 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
